Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Datametrex AI Ltd V.DM

Alternate Symbol(s):  DTMXF

Datametrex AI Limited is a technology-focused company with exposure to artificial intelligence, healthcare, and mobile gaming. It is focused on collecting, analyzing and presenting structured and unstructured data using machine learning and artificial intelligence. The Company's products include AnalyticsGPT, Cyber Security, and Healthcare. AnalyticsGPT platform scans vast data streams from... see more

TSXV:DM - Post Discussion

Datametrex AI Ltd > 25,000 tests/week in Q2
View:
Post by Resilience19 on Feb 15, 2021 10:42am

25,000 tests/week in Q2

This is only speculation at this time but given the tests/week having tripled from Q4 to Q1 (4,000/wk to 12,000/wk), I wouldn't be surprises, given the current context (variants threat, availability of non-intrusive spit test etc), to see test double again in Q2, to 25,000 or so. Furthermore, as DM appears to be building capacity, as demand increases, I wouldn't be surprised to see this figure, yet again, double to 50,000ish/wk during Q3. Afterwards, as nationwide immunization-driven herd immunity builds up, it may be that these figures will decrease, but that is highly dependent on whether additional new variants don't wreck havoc. In short, we may end up being in a linger term testing pattern, although margins would likely decrease as competition and tests availabilities increase. Regardless 2021 is bound to be a very interesting COVID-related income generating year at that current 12,000/wk tests is nimble compared to what's to come. My two cents.
Comment by MLorenzo on Feb 15, 2021 7:25pm
I agree that the weekly testing numbers should continue to increase and remain fairly constant. 50,000/wk in Q3 is very aggressive as testing is incremental not exponential, but the company should see the testing and capacity numbers increase for the forseable future. These numbers are also just based on Canadian sales, Gunter has spoken about major EU, Middle Eastern and African contracts which ...more  
Comment by Resilience19 on Feb 15, 2021 9:32pm
Yes I agree, 50,000/wk is a very aggressive figure but this is also a VERY rough guestimate only and bearing in mind all potential sources of testing (national and international). This said, I'm quite confident such a target would be achievable in the current context.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities